Last reviewed · How we verify
A Phase 2 Trial to Evaluate the Safety and Antitumor Activity of Pembrolizumab and OLApaRib (POLAR) Maintenance for Patients With Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination Deficiency and/or Exceptional Treatment Response to Platinum-Based Therapy
The study researchers think that combining the drugs pembrolizumab and olaparib (POLAR) may help people with this disease because pembrolizumab activates the immune system to fight cancer, and olaparib destroys cancer cells by preventing them from repairing damage to the genetic information that helps them survive and grow. The study researchers are doing this study to find out whether combining these drugs may be a more effective treatment for this cancer than taking olaparib alone.
Details
| Lead sponsor | Memorial Sloan Kettering Cancer Center |
|---|---|
| Phase | Phase 2 |
| Status | ACTIVE_NOT_RECRUITING |
| Enrolment | 63 |
| Start date | 2020-12-18 |
| Completion | 2027-01 |
Conditions
- Metastatic Pancreatic Ductal Adenocarcinoma
- Homologous Recombination Deficiency (HRD)
Interventions
- Pembrolizumab
- Olaparib
Primary outcomes
- Progression free survival (PFS) — 6 months
PFS is defined as the time from the initiation of study treatment to radiographic progression or death.
Countries
United States